FAM35A Inhibitors
FAM35A inhibitors refer to a class of chemical compounds specifically designed to suppress the function of the FAM35A protein. FAM35A, a protein encoded by the FAM35A gene, is implicated in various cellular processes, including DNA repair mechanisms. Inhibitors targeting this protein work by interfering with its ability to participate in the homologous recombination repair of double-strand breaks in DNA, a critical pathway for maintaining genomic stability. These inhibitors typically do so by binding to the protein and hindering its interaction with other components of the repair machinery, such as RAD51, thus preventing the proper assembly of the protein complexes necessary for effective DNA repair. The exact mechanism of inhibition can vary among different chemical compounds within this class, with some blocking the ATPase activity required for DNA strand exchange and others preventing the physical association of FAM35A with DNA or other proteins involved in the repair process.
The development of FAM35A inhibitors involves a nuanced understanding of the protein's structure and its role within the cell. By targeting specific domains within FAM35A, these inhibitors can achieve a high degree of specificity, ensuring minimal off-target effects on other proteins. For instance, some inhibitors in this class may be designed to interact with the OB-fold domain, a common feature in proteins involved in DNA processes, which is critical for FAM35A's function. Others might aim to destabilize the protein or its subunits, thereby preventing it from effectively carrying out its role in DNA repair. The result of such inhibition is an accumulation of DNA damage within the cell due to the crippled repair process, which can lead to genomic instability. By targeting the precise molecular interactions that FAM35A engages in, these inhibitors can exert a potent and specific effect on the protein's activity without broadly affecting other cellular pathways.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
A CDK4/6 inhibitor that disrupts the cell cycle. FAM35A is implicated in DNA repair processes which are tightly linked to the cell cycle. Inhibition of CDK4/6 by Palbociclib would indirectly suppress FAM35A activity by preventing cell cycle progression where FAM35A function is critical. | ||||||
Olaparib | 763113-22-0 | sc-302017 sc-302017A sc-302017B | 250 mg 500 mg 1 g | $210.00 $305.00 $495.00 | 10 | |
A PARP inhibitor that interferes with DNA repair mechanisms. Since FAM35A is involved in the repair of DNA, the use of Olaparib reduces the availability of PARP proteins that FAM35A may interact with, potentially inhibiting FAM35A's function in the DNA damage response. | ||||||
VE 821 | 1232410-49-9 | sc-475878 | 10 mg | $360.00 | ||
Targets ATR kinase, a key player in the response to DNA damage. FAM35A has a role in DNA repair, and by inhibiting ATR, VE-821 indirectly hampers the DNA damage response pathway, thereby reducing FAM35A's function in this process. | ||||||
2-allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-(4-(4-methylpiperazin-1-yl)phenylamino)-1,2-dihydropyrazolo[3,4-d]pyrimidin-3-one | 955365-80-7 | sc-483196 | 5 mg | $340.00 | 1 | |
Inhibits the WEE1 kinase which regulates cell cycle progression. FAM35A is associated with DNA repair during the cell cycle, and the inhibition of WEE1 by Adavosertib may diminish the role of FAM35A during the G2/M checkpoint. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
Inactivates PI3K, affecting AKT signaling. Since FAM35A is part of the DNA damage response, and PI3K/AKT pathway is involved in cell survival signals, LY294002 would indirectly reduce FAM35A's repair capacity by attenuating the survival pathways. | ||||||
AZD7762 | 860352-01-8 | sc-364423 | 2 mg | $107.00 | ||
Inhibits CHK1, which is essential for DNA damage checkpoint activation. FAM35A is involved in DNA repair, so inhibiting CHK1 with AZD7762 would disrupt the checkpoint control, possibly impairing FAM35A's ability to function in DNA repair. | ||||||
KU 60019 | 925701-46-8 | sc-363284 sc-363284A | 10 mg 50 mg | $248.00 $1035.00 | 1 | |
Inhibits ATM kinase, which is activated by DNA damage. FAM35A participates in DNA repair pathways, and inhibition of ATM by KU-60019 would indirectly inhibit FAM35A by compromising the signaling cascade necessary for its activation. | ||||||
NU 7441 | 503468-95-9 | sc-208107 | 5 mg | $357.00 | 10 | |
Specifically inhibits DNA-PKcs, a key enzyme in non-homologous end joining (NHEJ), a DNA repair pathway. Since FAM35A is involved in the DNA damage response, NU7441 would indirectly decrease FAM35A's activity by inhibiting a pathway it operates within. | ||||||
17-AAG | 75747-14-7 | sc-200641 sc-200641A | 1 mg 5 mg | $67.00 $156.00 | 16 | |
Inhibits HSP90 which is involved in stabilizing several client proteins, including those involved in DNA repair. The inhibition could impact FAM35A by destabilizing proteins that interact with or are upstream of FAM35A in the DNA repair pathway. | ||||||
Etoposide (VP-16) | 33419-42-0 | sc-3512B sc-3512 sc-3512A | 10 mg 100 mg 500 mg | $51.00 $231.00 $523.00 | 63 | |
Inhibits Topoisomerase II, which alters DNA topology. As FAM35A is implicated in DNA repair, the action of Etoposide could indirectly affect FAM35A's role by stabilizing DNA double-strand breaks, which FAM35A is suggested to help repair. | ||||||